Navigation Links
Advanced Life Sciences to Host Third Quarter 2007 Financial Results Conference Call and Live Webcast
Date:11/8/2007

CHICAGO, Nov. 8 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that it will host a conference call and live webcast at 9:00 a.m. Eastern Time on Thursday, November 15, 2007 to discuss the Company's third quarter financial results. Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, and other members of the management team will also present an update on the Company. A press release reporting the third quarter financial results will be issued after the U.S. stock markets close on Wednesday, November 14, 2007.

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of Advanced Life Sciences' corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866-510-0704 (domestic) or 617- 597-5362 (international). The passcode for the conference call is 57071751. A telephone replay of the call will also be available for 48 hours. Callers may access the telephone replay by dialing (domestic) 888-286-8010 or 617-801- 6888 (international), passcode 51192916.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at ht
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... 6, 2011 Biodel Inc. (Nasdaq: BIOD ... and CEO of Biodel, will present a corporate update ... January 13, 2011 at 9:30 a.m. Pacific Time (12:30 ... the development of new follow-on formulations of its lead ...
... OAKS, Calif. and MONROVIA, Calif., Jan. 6, 2011 ... announced today that they will collaborate to develop XmAb ... CD19 and CD32b.  XmAb5871 is currently in late-stage preclinical ... Under the terms of the agreement, Amgen has ...
... DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. (Nasdaq: ... results from its Phase 2b study of RDEA594 in ... treatment of gout, allopurinol.  Allopurinol currently accounts for greater ... prescription medications; however, in controlled trials, only 30-40% of ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7
(Date:4/23/2014)... The shale gas boom has transformed the energy ... locations, it could cause conflict among the energy ... resources, say researchers. They add that degraded water ... adequate safeguards. The feature article appears in the ... , Meagan S. Mauter and colleagues point out ...
(Date:4/23/2014)... fiction, or simply cli-fi, is a newly coined term for ... warming. New research from University of Copenhagen shows how these ... simulate the potential consequences of climate change and imagine other ... scientific data on changes in the atmosphere; it is also ... the books we read and the films we see. And ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... conducted at Western University (London, Canada) points to a ... (PTSD): utilising neurofeedback training to alter the plasticity of ... During neurofeedback, intentional control of one,s own ... brain-computer interface, which is able to represent graphically a ...
... those living with gastrointestinal disorders, such as ulcers or Crohn,s ... dietary changes. But what if one day treatment meant doing ... of inflamed or diseased tissues? That is where ... of Technology (MIT) are hoping their new study findings will ...
... Current pledges for greenhouse gas emission reductions are ... reach internationally agreed climate targets, according to new ... research teams coordinated by the International Institute for ... for Climate Impacts Research (PIK)., In the absence ...
Cached Biology News:Neurofeedback tunes key brain networks, improving subjective well-being in PTSD 2Manufacturing a new gut to treat GI diseases 2Continuing with pledge pathways to 2030 could push climate goals out of reach 2
... Synthesis Service provides you with ... knockdown any gene. We offer ... pairs with terminal dT nucleotides), ... lengths of your choice. Each ...
...
...
... Luminex 100 IS System is ideal for ... Beadlyte reagents. This system contains the new, ... by Luminex. The user can design specific ... The system has fully integrated graphing and ...
Biology Products: